MeiraGTx (MGTX) CEO Alexandria Forbes Buys 980,000 Shares

Alexandria Forbes, the President and CEO of MeiraGTx Holdings plc, made a significant move by acquiring 980,000 shares of the company on June 25, 2026. This transaction wasn't part of a pre-planned trading program and reflects Forbes' direct interest in the company's future.

Other Institutional Activity in MeiraGTx Holdings

Rubric Capital Management LP increased its holdings by 824,669 shares, bringing its total to 7 million shares valued at approximately $60.62 million, marking a 13.4% increase. Meanwhile, Millennium Management LLC added 289,309 shares, totaling 3,465,699 shares worth about $30.01 million, a 9.1% increase. Other major stakeholders like Sanofi and Johnson & Johnson maintained their positions without any changes.

MeiraGTx Holdings plc Stock Down 5.4%

Shares of NasdaqGS:MGTX traded near $12.54 on Tuesday. MeiraGTx Holdings has a market capitalization of approximately $1.12 billion. The company's forward P/E ratio is not meaningful as it is currently not profitable, and it has a beta of 1.257. The stock's 52-week range is between $6.31 and $12.28, with a 50-day moving average of $9.86 and a 200-day moving average of $8.52.

Recent Earnings

MeiraGTx reported revenue of $79.76 million, though it experienced a revenue decline of 84.8%. The company has a negative net margin of 151.1%, reflecting its current financial challenges. The next earnings report is anticipated on August 13, 2026.

Insider Buying and Selling at MeiraGTx Holdings plc

In addition to Alexandria Forbes' purchase, several other executives made notable acquisitions on June 25, 2026. Stuart Naylor, the Chief Scientific Officer, Ophthalmology, bought 70,000 shares. Robert Wollin, General Counsel and Secretary, acquired 100,000 shares, while Robert Zeldin, Chief Medical Officer, also purchased 100,000 shares. Richard Giroux, CFO & COO, matched Forbes' purchase, acquiring 980,000 shares. These transactions were not executed under Rule 10b5-1 plans.

Analysts Set New Price Targets

RBC Capital maintained its 'buy' rating with a $25 price target on May 15, 2026. Piper Sandler also kept a 'buy' rating, setting a $30 target on April 22, 2026. The consensus among analysts is a 'strong buy,' with a mean target price of $28.25.

About MeiraGTx Holdings

MeiraGTx Holdings plc is a clinical-stage genetic medicines company based in New York, specializing in developing treatments for serious diseases. The company focuses on therapies for ocular and neurodegenerative diseases, as well as xerostomia. It collaborates with major firms like Johnson & Johnson and Hologen Limited to advance its gene therapy research and development.

Bottom Line

Alexandria Forbes' significant share purchase underscores her commitment to MeiraGTx Holdings. Investors often monitor insider transactions as they can provide insights into a company's future prospects. However, it's important to note that such transactions are historical and may not reflect current positions. MeiraGTx's stock performance and analyst ratings suggest potential growth, making it a company to watch.